Inactive Instrument

Press Releases ContraVir Pharmaceuticals Inc Nasdaq

Equities

US21234W1036

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

Hepion Pharmaceuticals Initiates Wind-Down Activities in Phase 2b 'ASCEND-NASH' Trial	04-22	AQ
Hepion Pharmaceuticals Initiates Wind-Down Activities in Phase 2b ‘ASCEND-NASH’ Trial	04-19	AQ
Hepion Pharmaceuticals Strengthens Board of Directors with Appointment of Michael Purcell	03-06	AQ
Hepion Pharmaceuticals Announces Exercise of Warrants for Approximately $2.0 Million Aggregate Gross Proceeds	02-16	AQ
Hepion Pharmaceuticals to Present at NASH-TAG 2024	01-03	AQ
Hepion Pharmaceuticals Announces Restructuring Plan to Enhance Shareholder Value and Management Changes	12-07	AQ
Hepion Pharmaceuticals to Present at the 7th Obesity & NASH Drug Development Summit	11-28	AQ
Hepion Pharmaceuticals Announces Major Reductions in Liver Stiffness with Rencofilstat Treatment in 17-week Phase 2 Study of Advanced (F3) MASH Liver Disease	11-13	AQ
Hepion Pharmaceuticals Schedules Conference Call to Review Additional Efficacy Data from Phase 2 ‘ALTITUDE-NASH’ Liver Function Trial of Rencofilstat	11-10	AQ
Hepion Pharmaceuticals’ Rencofilstat Demonstrates Anti-Cancer Activity in Hepatitis C-Associated Cancer Model	23-10-25	AQ
Hepion Pharmaceuticals Announces $5.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market under Nasdaq Rules	23-09-29	AQ
Hepion Pharmaceuticals to Participate in 2023 Cantor Global Healthcare Conference	23-09-21	AQ
New Anti-Cancer Opportunities Revealed for Hepion Pharmaceuticals’ Rencofilstat in Cancer Screening Program	23-09-21	AQ
Hepion Pharmaceuticals Discovers Novel Rencofilstat Action in Liver Cancer	23-09-19	AQ
Rencofilstat Produces Positive Outcomes in Translational Study on Idiopathic Pulmonary Fibrosis	23-09-14	AQ
Hepion Pharmaceuticals Announces Management Changes	23-09-06	AQ
Hepion Pharmaceuticals to Present Two Posters at EASL International Liver Congress™ 2023	23-06-15	AQ
Hepion Pharmaceuticals Announces Passing of Key Safety Milestone in Phase 2b ‘ASCEND-NASH’ Trial of Rencofilstat	23-06-15	AQ
Hepion Pharmaceuticals to Highlight AI-POWR™ at the 2023 CSPS Annual Symposium: The Next Frontiers in Pharmaceutical Sciences	23-05-24	AQ
Hepion Pharmaceuticals’ Phase 2 ‘ALTITUDE-NASH’ Trial Achieves Primary and Secondary Endpoints, Including Improvement in Liver Function and Multiple NASH Biomarkers	23-05-22	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases ContraVir Pharmaceuticals Inc Nasdaq

Equities

US21234W1036

Press Releases

Filters